Accuracy of ADC ratio in discriminating true and false positives in multiparametric prostatic MRI.


Journal

European journal of radiology
ISSN: 1872-7727
Titre abrégé: Eur J Radiol
Pays: Ireland
ID NLM: 8106411

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 26 03 2020
revised: 14 04 2020
accepted: 15 04 2020
pubmed: 11 5 2020
medline: 8 1 2021
entrez: 11 5 2020
Statut: ppublish

Résumé

Our goal was to evaluate the usefulness of apparent diffusion coefficient (ADC) ratios in discriminating true from false positives in multiparametric (mp) prostate MRI in clinical practice. We retrospectively evaluated 98 prostate lesions in a series of 73 patients who had undergone prostate mpMRI and standard 12-core prostatic biopsy in our institution from 2016 to 2018. Two experienced radiologists performed double blind ADC value quantifications of both MRI-identified lesions and apparently benign contralateral prostatic parenchyma in a circular region of interest (ROI) of ∼10 mm For Reader 1, the area under the ROC curve (AUC) of ADC ratio mean and ADC ratio min-max were 0.72 and 0.67, respectively, whereas for Reader 2 these values were 0.74 and 0.71, respectively. The best cut-off values for ADC ratio means were ≥ 0.5 (Reader 1) and ≥ 0.6 (Reader 2), with a sensitivity of 76.3 % and 84.2 % and a specificity of 51.7 % and 50 %, respectively. Moreover, based on a threshold of 0.6, no clinically significant prostate cancer (csPCa) was missed by Reader 1, while only one went unnoticed by Reader 2. The ADC ratio is a useful and moderately accurate complementary tool to diagnose prostate cancer in the mp-MRI.

Identifiants

pubmed: 32387923
pii: S0720-048X(20)30213-8
doi: 10.1016/j.ejrad.2020.109024
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109024

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Zeno Falaschi (Z)

Azienda Ospedaliero-Universitaria Maggiore della Carita, Novara, NO, Italy. Electronic address: zenofalaschi@gmail.com.

Martina Valenti (M)

Azienda Ospedaliero-Universitaria Maggiore della Carita, Novara, NO, Italy.

Giuseppe Lanzo (G)

Azienda Ospedaliero-Universitaria Maggiore della Carita, Novara, NO, Italy.

Silvia Attanasio (S)

Azienda Ospedaliero-Universitaria Maggiore della Carita, Novara, NO, Italy.

Eleonora Valentini (E)

Azienda Ospedaliero-Universitaria Maggiore della Carita, Novara, NO, Italy.

Lara Isabel García Navarro (LI)

Azienda Ospedaliero-Universitaria Maggiore della Carita, Novara, NO, Italy.

Ferruccio Aquilini (F)

Azienda Ospedaliero-Univarsitaria Pisana, Pisa, PI, Italy.

Alessandro Stecco (A)

Azienda Ospedaliero-Universitaria Maggiore della Carita, Novara, NO, Italy.

Alessandro Carriero (A)

Azienda Ospedaliero-Universitaria Maggiore della Carita, Novara, NO, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH